Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2011

View Archived Issues

Astellas Pharma reviews progress of second quarter fiscal year 2011

First-in-human data released on candidate hepatitis C therapy

AstraZeneca reviews progress of third quarter 2011

Hepatitis C virus resistance characterized in multiple-dose trial of GS-5885

LB-80380 compared to entecavir in phase IIb trial

Tocilizumab assessed in large vessel vasculitis

Ampio Pharmaceuticals reports on Ampion for nasal inflammation

Scancell to receive second tranche payment for antibody portfolio

Novel clinical data and analyses presented on Regeneron's rilonacept

PRT-201 shows promise in patients with kidney disease on hemodialysis

New PHD2 inhibitors for anemia patented

Merck & Co. prepares novel fatty-acid amide hydrolase 1 inhibitors

Novel lysophospholipid S1P1 receptor agonists disclosed by Bristol-Myers Squibb

Glenmark Pharmaceuticals claims novel phosphodiesterase 10A inhibitors

Scientists at Janssen synthesize new ketohexokinase inhibitors

Pharmacokinetics and safety of E-7050 assessed in humans

High-strength antidepressant gains FDA approval

FDA removes clinical hold on Helix BioPharma IND application

Analgesia seen with NP-2 in phase I study

Ablynx announces proof-of-concept phase II data on ALX-0081

FDA schedules review of NDA for progesterone vaginal gel

Alimera receives complete response letter for Iluvien NDA

EC withdraws marketing authorization for Ablavar

Phase III study in MS meets primary endpoints

Kyowa Hakko Kirin and Cephalon begin clinical testing of CEP-37250

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...